Open AccessP822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG‐ACTING ANTI‐C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT‐MEDIATED DISEASES
Author(s) -
KHOO C. M.,
SONG X.,
WU Q.,
COX G. F.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846172.64321.0a
Subject(s) - medicine , eculizumab , pharmacodynamics , pharmacokinetics , paroxysmal nocturnal hemoglobinuria , tolerability , clinical endpoint , placebo , adverse effect , pharmacology , antibody , immunology , gastroenterology , complement system , clinical trial , pathology , alternative medicine